Japanese healthcare technology company finds synergy with Indian market and Medinippon’s network

April 27, 2026

Medinippon provides services from market study, sales & marketing effort, and approval by Ministry of Health, Govt of India (CDSCO) for successful business launch by Create Medic Japan, a company listed in Tokyo stock exchange

Please see details in the following article:

Create Medic Launch Ceremony

The launch ceremony of Indian subsidiary of Create Medic, Japan in Chennai, 15th April 2026; Hon’ble Consul General of Japan Mr. Muneo Takahashi delivering the Chief Guest’s address;

In the pic L>R: Mr. Kousuke Suto, GM-Create Medic India, Prof. Shyamkumar N. Keshava, Dept. of Interventional Radiology, CMC, Vellore, Mr. Osamu Imazawa, President, Create Medic Japan, Mr. Katsuaki Yamane, MD, Create Medic India & Dr. Rajappa Senthilkumar, Director, MediNippon Healthcare.

In the pic L>R: Prof. Shyamkumar Keshava (Prof. of Radiology, CMC Vellore), Mr. Muneo Takahashi (Hon`ble Consul General of Japan, Chennai, India), Mr. Osamu Imazawa (President, Create Medic Co Ltd, Japan), Mr. Katsuaki Yamane (Managing Director, Create Medic Pvt Ltd, India), Mr. Kousuke Suto (Director, Create Medic Pvt Ltd, India), Prof. S. Arumugam (Head, Institute of Sports Sciences, Sri Ramachandra Institute of Higher Education, Chennai, India), Dr. Rajappa Senthilkumar (Director, Create Medic Pvt Ltd, India) 

Vietnam’s Role in Asian Medical Tourism; NCRM & GN Corporation spearhead tech-transfer

October 29, 2025

Colorectal cancer, Lung Cancer and Liver Cancer patients report longer survival and improved quality of life after AIET cell therapy using NK cells and T Cells, presented in NCRM NICHE annual conference.

Please see details in the following BiopharmaAPAC article:

BiopharmaAPAC

At the MENA Conference on Rare DiData presented in IFPA 7^th World Psoriasis conference, in Stockholm, Sweden

04 July 2024

A breakthrough improvement in clinical signs and symptoms of Psoriasis Vulgaris proven by skin biopsy, following oral consumption of  Neu REFIX Beta glucan for 28 days in a clinical trial conducted by the team of Prof. J. Thadeus, Head, Dept. of Dermatology, Govt. Thoothukudi Medical College, taking technical advice from Japanese scientists was presented in the International Federation of Psoriasis Associations (IFPA) Conference; The 7^th World Conference of Psoriasis and Psoriatic Arthritis, held in June in Stockholm, Sweden. Prof. J. Suresh Durai, of Tirunelveli Medical College and Dr. Ichiro Miura of Obihiro Hospital, Hokkaido, Japan, meticulously evaluated the skin biopsy findings to confirm the improvement.

Psoriasis is a multi-factorial inflammatory skin disease that affects 2~3% of the total population.  About 20~30% of patients may progress to psoriatic arthritis, which affects the joints. The disease pathology being highly complex, and a definitive cure is not currently available, disease modifying treatments remain the mainstream of management. Based on the earlier reports by Japanese scientists in pre-clinical and clinical studies using Neu REFIX Beta glucans, Dr. Thadeus conducted this trial in 30 patients; 20 of them took Neu REFIX along with conventional therapies while the other 10 had only conventional therapies. In the study, 80% of the patients who consumed Neu REFIX showed improvements in their skin condition. Infiltration of lymphocytes in skin, the cause of skin lesions and inflammation were significantly reduced in them compared to those who had only conventional treatment. PASI Score, which is the gold standard for evaluating the clinical severity also reduced significantly in Neu REFIX group. Dr. Thadeus is planning to organize an International Seminar to commemorate the World Psoriasis Day in October where the findings will also be shared.

This journey started in 2009, has gathered evidence of safety of this allergen-free Neu REFIX compound in KK-Ay mice, SD rats, NASH and mdx mice models; clinical studies in healthy volunteers and Duchenne muscular Dystrophy (DMD) patients besides its efficacy as an anti-inflammatory, immunomodulating adjuvant along with beneficial gut microbiome reconstitution, is now a hope to Psoriasis patients, added the scientists.

Please visit the Hindu news from here.

11Aug2023

Japanese medical device manufactures, Create Medic Co Ltd launched their Cliny PEG kits in India ably supported by Medinippon Healthcare Pvt Ltd, a sister company of GN Corporation for market survey, promotion and CDSCO registration; More products such as microcatheters to be launched in the near future.

Please see the article Bio StartUps for further details.

06July 2023

June 30, Chennai; Japanese scientists, research collaborators to Nichi-in Centre for Regenerative Medicine (NCRM) have reported an increased yield of Beta 1,3-1,6 glucans in the produce, as an exo-polysaccharide by the yeast Aureobasidium Pullulans employing improvised culture methodology.

Please visit press release here.

N-163 strain of Aureobasidium Pullulans produced Beta 1,3-1,6 glucans (‘Neu REFIX‘) improved butyrate and beneficial gut microbiome relavent to anti-aging phenomemon in NASH mice models; The Hindu Business Line

03Oct 2022

Combination with conventional therapy

Treatment of cancer using one’s own immune cells, natural killer (NK) cells and T-cells, called autologous immune enhancement cell therapy (AIET) administered along with conventional chemotherapy, radiotherapy and surgery, practiced in Japan for long is now offered in Vinmec hospital, Hanoi, Vietnam, following technology transfer by GN Corporation.

Cancer patients from neighboring countries are now visiting Vinmec hospital for this treatment. Autologous immune-cell therapy, regulated by the regenerative medicine law in Japan, uses lab-expanded autologous immune cells, without animal proteins or genetic manipulation.

Benefits of AIET & hyperthermia

While increase in survival rate in cancer patients is reported by adding immune-cell therapy to conventional treatment regimen, the Hyperthermia system developed in Japan further improves outcome of cancer treatment as it targets the cancer cells which are vulnerable to damage at a higher temperature of 42 Deg Celsius.

To propagate these add-on cancer treatments to overseas hospitals, GNC Japan is collaborating with Yamamoto Vinita, manufacturers of Thermotron, the first hyperthermia equipment to treat malignant tumors, approved in Japan which has been installed in more than 300 hospitals in six countries. The latest Thermotron-RF8-EX version is a stand-alone system with Eight MHZ radiofrequency, uses electrodes of different sizes in combination to treat superficial and deep-seated solid tumors of the entire body except eye and brain.

Attracting attention from overseas oncology hospitals

Hospitals in Japan offering these cancer therapies receive patients from abroad for treatment. Recently overseas cancer hospitals have started showing interest in adding these two therapies to their existing systems for cancer treatment in clinical oncology services.

Accomplishments of GN Corporation, in adding value to Japanese technologies by inter-disciplinary interaction, developing novel healthcare solutions and global propagation were featured by Govt of Japan in the official YouTube channel of the prime minister’s office of Japan, JETRO Invest in Japan portal and a feature story sponsored by Govt of Japan in Bloomberg.

Please visit Businesswire for press release.

Please see the article of  Japan Today

GN Corporation and Edogawa hospital, Tokyo will be hosting an international webinar on novel solutions to address urethral stricture using cell based therapies on the 16^th Oct (Sun) between 1100~1210 Hrs as a virtual event in which Dr. Akio Horiguchi, top most urologist in the management of Urethral stricture in Japan (National defence medical college, Koku-Koen), Dr. Dmitriy Nikolavsky from Upstate University New York, USA  and Dr Suryaprakash Vaddi from Yashoda Hospital India, the inventor of BEES-HAUS procedure will deliver talks. This program is conducted as a part of XVII inaugural anniversary commemorative academic event of Nichi-in Centre for Regenerative Medicine , a collaborator to Edogawa Evolutionary Lab of Science (EELS), JBM Inc., and GN corporation Co Ltd, Japan.  

Urethral stricture in men is a disease, that affects adult men especially with an increasing incidence after the age 55. Major causes though in developing countries are trauma and infection, in developed nations, it occurs either as an iatrogenic sequalae such as post radiotherapy complication after prostate cancer treatment or surgical resection for hypertrophy of the prostate. Idiopathic cause remains around 25% globally. Despite several invasive approaches at late stage such as buccal mucosal tissue based urethroplasty to less invasive cystoscopy approaches such as urethrotomy and/or dilatation, the recurrence of stricture is an unresolved issue. To solve this disease, the Edogawa hospital through their EELS research team has collaborated with NCRM India and GN corporation who have successfully demonstrated that using buccal mucosal tissue derived cells, instead of a big tissue graft we could manage urethral stricture through a minimally invasive approach. In this approach called BEES-HAUS , a small tissue of the patient’s own buccal mucosa is harvested as an out-patient procedure, then cells isolated in the lab and cultured using a 3D polymer scaffold platform developed by japanese polymer chemists and tissue engineering specialists. After expanding for 10~15 days, the cells are transplanted encapsuled in polymer scaffold after removing the fibrous adhesions.. Initaly pilot study in six patients with a three-year follow-up has yielded safety and confirmed the successful engrafting of transplanted cells to the site of stricture. Dr Horiguchi and his colleagues in NDMC, Japan adapted the method with the help of EELS and JBM to reproduce in animal models and could prove the same for safety and efficacy in pre-clinical studies and now are moving towards a larger clinical study in Japan in Edogawa Hospital.  

Dr Dmitriy Nikolavsky from USA is working on similar directions but with a modified approach while Dr Suryaprakash who initiated the Bees-haus procedure will share their perspectives of this complex disease during the webinar. To join, either you need do register at the URL: https://www.ncrmniche.org/registration/ps2022.asp, or you can scan the QR code in the image attached. Full program is available in the URL: https://www.ncrmniche.org/ncrmniche2022/agenda.html.  

Dr Shojiro Katoh, President of Edogawa Hospital explained that the Edogawa hospital would like to have concern for such minor and even rare diseases, being a part of Jinseisha, a social welfare organization and would like to become a global hub for propagation both basic and translational science taking shape as a worthy solution to such unmet needs. 

To participate in the webinar, please register at URL: https://www.ncrmniche.org/registration/ps2022.asp or scan the QR code in the attached image.

The full program of NCRM NICHE 2022 is available at https://www.ncrmniche.org/ncrmniche2022/agenda.html.

Press release : Kyodo News PR Wire

GN Corporation has published a paper on its beta glucan product neu REFIX in the Journal of Clinical and Experimental Hepatology.

The paper, “Hepatoprotective effects of beta-1,3-1,6-glucan from black yeast in a mouse model of non-alcoholic fatty liver” (https://doi.org/10.1016/j.jceh.2022.06.008), reported that beta-glucan showed beneficial results against a disease called non-alcoholic fatty liver (NASH) in the animal study.

Now that neu REFIX has been shown to have an immunomodulatory function and control inflammation and fibrosis in NASH, a new short-term clinical trial is underway for Duchenne muscular dystrophy, a rare disease caused by a genetic mutation that has similar pathophysiology. The study will focus on inflammation and fibrosis biomarkers, similar to the study in NASH (preprint article: https://doi.org/10.1101/2021.12.13.21267706 ).

The Duchenne Muscular Dystrophy Study Group Duchenne Awareness Day will be held on September 4, 2012. Dr. Yoshitsugu Aoki, Director of Gene Therapy Research, National Center of Neurology and Psychiatry (NCNP), will give a special lecture, and Dr. Raghavan of Department of Pediatric Neurology, JAICARE, Tamil Nadu, India, will present a clinical trial of neu REFIX in India.

Please see Kyodo News PR Wire press release.